ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 123

Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension

Richard Bell1, Maria de la Luz Garcia-Hernandez2, Javier Rangel-Moreno3, Christopher T. Ritchlin2, Homaira Rahimi4 and Edward Schwarz5, 1Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 2Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, 3Division of Allergy, Immunology and Rheumatology and Center for Musculoskeletal Research School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 4Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, 5Orthopedeatrics, University of Rochester, Rochester, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Connective tissue diseases, Heart disease, pulmonary complications, rheumatic disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiopulmonary disease is a severe comorbidity in many connective tissue diseases (CTD). Rheumatoid arthritis, systemic sclerosis, and systemic lupus patients are all at increased risk of pulmonary complications and mortality secondary to these complications. Specifically, pulmonary arteriole vasculopathy can lead to right ventricle hypertrophy and eventually, right heart failure. Recently, TNF transgenic (TNF-Tg) mice with inflammatory erosive arthritis was described to have inflammatory interstitial lung disease with significant arteriole thickening, concomitant with right ventricle hypertrophy. However, the source of the pathogenic TNF in this model remains unknown.  Thus, we performed adoptive transfer experiments to test the hypothesis that non-hematopoietic derived TNF mediates pulmonary vasculopathy in the setting of inflammatory arthritis.

Methods: Female TNF-Tg and WT littermates were treated with a 10 Gy split dose at 6 weeks of age, and syngeneic TNF-Tg or WT bone marrow was transferred back into the irradiated mice. Following bone marrow reconstitution, the mice were euthanized at 4-5 months of age for histology of the hearts and lungs. Histomorphometry was performed to assess, right ventricular (RV) area, lung cellular area, and pulmonary arteriole thickness.

Results: Representative images (Figure 1A-E) of the hearts show an increase in RV area (Arrows) in the TNF-Tg and the TNF-Tg donor into TNF-Tg recipients (TNF-Tg → TNF-Tg) compared to the WT mice (5.4±1.2 and 3.7±0.6 vs 2.0±0.6 mm2, p<0.05). However, the WT recipient of TNF-Tg bone marrow (TNF-Tg → WT) showed no signs of ventricular hypertrophy. In contrast, the TNF-Tg recipient of WT bone marrow (WT → TNF-Tg) displayed increased RV area compared to the TNF-Tg → WT mice (4.8±1.1 vs 1.3±0.1 mm3, p<0.05). The lung cellular infiltrate is also reduced in the TNF-Tg → WT compared to the WT → TNF-Tg (Arrows, Figure 2 A-C, 6.8±0.2 vs 12.5±1.3%, p<0.05), as well as the pulmonary arteriole thickness (Arrows, Figure 2 D-E, 29.5±8.4 vs 38.3±14.2 μm, p<0.05).

Conclusion: We have previously described significant cardiopulmonary disease in the TNF-Tg mouse. Here, we interrogated the role of the non-hematopoietic derived TNF to drive cardiopulmonary pathology associated with connective tissue disorders. These data suggest a critical role of tissue resident cells and their inflammatory profile in the development of vasculopathy and pulmonary hypertension.

 


Disclosure: R. Bell, None; M. D. L. L. Garcia-Hernandez, None; J. Rangel-Moreno, None; C. T. Ritchlin, AbbVie, Amgen, UCB, 2,AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer Inc, 5; H. Rahimi, None; E. Schwarz, None.

To cite this abstract in AMA style:

Bell R, Garcia-Hernandez MDLL, Rangel-Moreno J, Ritchlin CT, Rahimi H, Schwarz E. Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/non-hematopoietic-derived-tnf-drives-pulmonary-vasculopathy-a-new-model-of-ctd-associated-pulmonary-hypertension/. Accessed July 4, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-hematopoietic-derived-tnf-drives-pulmonary-vasculopathy-a-new-model-of-ctd-associated-pulmonary-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies